Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Brief Summary: The primary objective of this research is to compare the need for intubation and mechanical ventilation in the first seven days of life for infants with respiratory distress syndrome (RDS) on nasal continuous positive airway pressure (nCPAP) who receive surfactant via a Laryngeal Mask Airway (LMA) with those who are maintained on nCPAP and do not receive surfactant.


Options:
A: Arm Label: nCPAP Control Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal continuous positive airway pressure (nCPAP) | Arm Label: LMA Group; Type: EXPERIMENTAL; Interventions: Device: Nasal continuous positive airway pressure (nCPAP), Device: Laryngeal Mask Airway (LMA) to deliver surfactant, Drug: Surfactants, Pulmonary | Intervention Type: DEVICE; Name: Nasal continuous positive airway pressure (nCPAP); Assigned to Arm(s): LMA Group, nCPAP Control Group | Intervention Type: DEVICE; Name: Laryngeal Mask Airway (LMA) to deliver surfactant; Assigned to Arm(s): LMA Group | Intervention Type: DRUG; Name: Surfactants, Pulmonary; Assigned to Arm(s): LMA Group
B: Arm Label: Endotracheal intubation; Type: ACTIVE_COMPARATOR; Interventions: Device: Endotracheal intubation, Drug: remifentanil | Arm Label: Laryngeal mask airway; Type: EXPERIMENTAL; Interventions: Device: Laryngeal mask airway | Intervention Type: DEVICE; Name: Endotracheal intubation; Assigned to Arm(s): Endotracheal intubation | Intervention Type: DEVICE; Name: Laryngeal mask airway; Assigned to Arm(s): Laryngeal mask airway | Intervention Type: DRUG; Name: remifentanil; Assigned to Arm(s): Endotracheal intubation
C: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen
D: Arm Label: Supraglottic airway; Type: EXPERIMENTAL; Interventions: Device: Supraglottic airway | Arm Label: Face-mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Face-mask | Intervention Type: DEVICE; Name: Supraglottic airway; Assigned to Arm(s): Supraglottic airway | Intervention Type: DEVICE; Name: Face-mask; Assigned to Arm(s): Face-mask

Answer: A